

Application Serial No. 10/025,272
Amendment dated July 9, 2004
Reply to Office Action mailed March 9, 2004

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-8 (canceled)

Claim 9 (currently amended): A kit for visualizing cellular organelles and/or cytoskeletons of cells in tissue or in cell suspension comprising

a formulation comprising at least one tetrazolium salt selected from the group consisting of p-Anisyl Blue Tetrazolium Chloride, p-Anisyl-p-Nitro Blue Tetrazolium Chloride, Thiazolyl blue (2-2'-Benzothiazolyl-5-styryl-3-(4'-phthalhydrazidyl) tetrazolium chloride), Blue tetrazolium chloride, 2-(2'-Benzothiazolyl)-5-styryl-3-(4'-phthalhydrazidyl)-tetrazolium chloride, 5-Cyano-2,3-ditolyl tetrazolium chloride, [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl]tetrazolium Bromide, 1-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, Distyryl nitroblue tetrazolium chloride, (1H)-tetrazole, Iodonitrotetrazolium chloride, Iodo Nitro Tetrazolium Violet Chloride, p-iodo nitrotetrazolium violet, (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyltetrazolium chloride, 2-(p-iodophenyl)-p-nitrophenyl-5-phenyltetrazolium chloride, m-Nitro Blue Tetrazolium Chloride, m-Nitro Neotetrazolium Chloride, 2,2-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium salt, tetrazolium bromide, thiazolyl blue tetrazolium bromide, 3-4,5-dimethylthiazol-2-yl-2,5-diphenyltetrazolium bromide, Nitro Blue Monotetrazolium Chloride, p-Nitro Blue Tetrazolium Chloride, 2,2'-di-nitrophenyl-5,5'-diphenyl-3,3'-(3,3'-dimethoxy-4,4'-diphenylene)ditetrazolium chloride, Neotetrazolium chloride, 2,2',5,5'-Tetraphenyl-3,3'(p-diphenylene)-ditetrazolium chloride, Nitrotetrazolium Violet; 3,3'-dimethoxy(1,1'-biphenyl)-4,4'-diyl]-bis(2,5-diphenyl-2H-tetrazolium) dichloride, o-Tolyl Tetrazolium Red, sodium 3'-[1-[(phenylamino)-carbonyl]-3,4-tetrazolium]-bis(4-methoxy-6-

Application Serial No. 10/025,272
Amendment dated July 9, 2004
Reply to Office Action mailed March 9, 2004

nitro)benzene-sulfonic acid hydrate, p-Nitro Blue Tetrazolium Chloride, Piperonyl Tetrazolium Blue, p-Tolyl Tetrazolium Red, Thiocarbamyl nitro blue tetrazolium chloride, 2,2'-di-p-nitrophenyl-5,5'-di-p-thiocarbamylphenyl-3,3'[3,3'-dimethoxy-4,4'-biphenylene]-ditetrazolium chloride, Tetranitroblue tetrazolium chloride, 1,3,5-triphenyltetrazolium, Tetrazolium Red, 2,3,5-triphenyltetrazolium chloride), Tetrazolium violet, Violet Tetrazolium, 2,3,5-Triphenyl-2-H-tetrazolium chloride, 2,5-diphenyl-3-[α -naphthyl]-tetrazolium chloride, 2,5-diphenyl-3-[1-naphthyl]-2H-tetrazolium chloride, veratryl tetrazolium blue, 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate, and 2,2-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide;

an inhibitor of succinate dehydrogenase; and

a pharmaceutically acceptable carrier medium selected from the group consisting of culture medium, emulsifying agent and pH buffering agent.

Claim 10 (original): A kit of claim 9, wherein said cellular organelle and/or cytoskeleton is selected from the group consisting of mitochondrion, chromosomes, nucleosome, chromatin, nuclei, nuclear matrix, nuclear lamina, core filaments, nuclear envelope, nuclear pore complexes, nuclear membranes, centromere, centrosome, centrioles, pericentriolar material, pericentrins, mitotic spindle, spindle pole bodies, contractile rings, kinetochore, proteasomes, telomere, plasma membranes, Golgi complexes, Golgi apparatus, endoplasmic reticulum, endosomes, peroxisomes, phagosomes, ribosomes, membrane skeleton, microvilli, cilia, flagella, microfilaments, actin filaments, microtubules, contractile ring, and intermediate filaments.

Claim 11 (cancelled)

Claim 12 (cancelled)

Application Serial No. 10/025,272
Amendment dated July 9, 2004
Reply to Office Action mailed March 9, 2004

Claim 13 (original): A kit of claim 9, wherein said tissue or cell sample is selected from the group consisting of normal mammalian tissue or cell, pathologic mammalian tissue or cell, neoplastic tissue or cell, vegetable, microorganism, and parasite.

Claim 14 (currently amended): A kit of claim 9, wherein said neoplastic tissue or cell is selected from the group consisting of carcinoma, sarcoma, leukemia, or lymphoma.

Claim 15 (original): A kit of claim 9, wherein said neoplastic tissue or cell is selected from the group consisting of acute lymphocytic leukemia, acute myelocytic leukemia, acoustic neuroma, adenocarcinoma, angiosarcoma, astrocytoma, basal cell carcinoma, bile duct carcinoma, bladder carcinoma, bone originated tumor, bone sarcoma, brain tumor, breast cancer, bronchogenic carcinoma, carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic lymphocytic leukemia, colon carcinoma, craniopharyngioma, cystadenocarcinoma, embryonal carcinoma, endotheliosarcoma, ependymoma, epithelial carcinoma, esophageal carcinoma, Ewing's tumor, fibrosarcoma, glioma, heavy chain disease, hemangioblastoma, hepatic carcinoma, hodgkin's lymphoma, leiomyosarcoma, leukemia, liposarcoma, lung carcinoma, lymphangioendotheliosarcoma, lymphangiosarcoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myxosarcoma, neuroblastoma, non-Hodgkin's lymphoma, pancreatic cancer, oligodendroglioma, osteogenic sarcoma, ovarian cancer, pancreatic carcinoma, papillary carcinoma, papillary adenocarcinoma, pinealoma, polycythemia vera, acute promyelocytic leukemia, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, small cell lung carcinoma, squamous cell carcinoma, stomach carcinoma, synovioma, sweat gland carcinoma, testicular tumor, uterus carcinoma, Waldenstrom's macroglobulinemia, Wilms' tumor, and the endothelial cells thereof.

Application Serial No. 10/025,272
Amendment dated July 9, 2004
Reply to Office Action mailed March 9, 2004

Claim 16 (currently amended): The kit of Claim 9 ~~11~~, wherein the succinate dehydrogenase inhibitor is nitropropionic acid.